AOD9604
Research compoundaka AOD-9604, hGH fragment 176-191
A GH fragment marketed for fat loss. The trials didn't deliver.
Mechanism
A synthetic copy of the tail end of growth hormone (the 176-191 fragment), pitched as fat-burning without touching blood sugar or growth. Nice theory. The obesity trials missed their endpoints.
Regulatory & Safety Status
Flopped in obesity trials and isn't approved. Sold as a research chemical on the strength of the marketing, not the data.
Research
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Latest AOD9604 research